NLRP3 Inhibitor Compounds for Selective Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for small molecules that can modulate NLRP3 activity to treat various inflammatory and degenerative diseases, as dysregulation of NLRP3 has been linked to conditions such as NASH, atherosclerosis, Alzheimer's disease, Parkinson's disease, diabetes, and autoinflammatory diseases, among others.
Innovation Solution
Development of compounds of Formula (I), (I'), and (I'') that inhibit NLRP3 activity, including pharmaceutically acceptable salts, solvates, clathrates, hydrates, stereoisomers, or tautomers, which can be administered to treat diseases associated with NLRP3 hyperactivation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NLRP3 is activated to fight infections and clear damaged cells, then immune defense is improved, but uncontrolled activation leads to chronic inflammation and tissue damage
Solution Approach 1:
The patent applies parameter changes by developing small molecule compounds that specifically modulate the activation threshold and intensity of NLRP3. These compounds alter the biochemical parameters of NLRP3 signaling, enabling selective suppression of pathological activation while preserving protective immune responses. The compounds achieve this by binding to specific sites on NLRP3 and modulating its conformational changes and downstream signaling intensity.
Solution Approach 2:
The patent implements dynamics by creating NLRP3 modulators that can dynamically adjust immune response intensity based on physiological context. The compounds enable reversible modulation of NLRP3 activity, allowing the system to switch between protective and suppressive states as needed. This dynamic control is achieved through reversible binding mechanisms and dose-dependent effects that preserve physiological regulation.
2Reliability
If small molecules are designed to inhibit NLRP3, then therapeutic effectiveness is improved, but selectivity and off-target effects become critical challenges
Solution Approach 1:
The patent applies local quality by designing small molecules with specific structural features that target particular regions or conformations of NLRP3. The compounds exhibit localized binding to specific pockets or interfaces on NLRP3 that are unique to this protein family member, ensuring selective inhibition. This is achieved through careful molecular design that exploits structural nuances of NLRP3 compared to related inflammasomes.
Solution Approach 2:
The patent uses intermediary mechanisms by developing compounds that indirectly modulate NLRP3 activity through intermediate binding steps or allosteric regulation. Rather than directly blocking the active site, some compounds act as allosteric modulators that influence NLRP3 conformation and activity through intermediate structural changes. This intermediary approach enhances selectivity by targeting unique regulatory mechanisms of NLRP3.
Data Source
AI summary
The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):